Expert perspectives on the ALPINE trial of zanubrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.
Transcript:
Andrew H. Lipsky, MD: [The ALPINE trial; NCT03734016] was an international phase 3 trial of zanubrutinib vs ibrutinib in over 650 patients with relapsing refractory CLL [chronic lymphocytic leukemia]. The patients received either zanubrutinib 160 [mg twice a day] or ibrutinib 420 mg daily. The trial assessed the overall response rate with secondary end points including progression-free survival [PFS].
At a median follow-up of 29.6 months, zanubrutinib was found to be superior to ibrutinib with respect to an overall response rate that was 86% vs 75%. More importantly, it also demonstrated an improved progression-free survival. At 24 months the investigator-assessed rates of PFS were 78.4% in the zanubrutinib group, and 65.9% in the ibrutinib group with the hazard ratio for progression of 0.65. And, of course, those outcomes were actually similar when assessed by an independent review committee. Importantly also, among patients with a 17p deletion, a TP53 mutation, or both, the patients who received zanubrutinib also had a longer PFS than those who received ibrutinib with a hazard ratio of 0.53. Also importantly, the safety profile of zanubrutinib was generally better than that of ibrutinib with fewer adverse events leading to treatment discontinuation, and fewer cardiac events, including fewer cardiac events leading to treatment discontinuation or death.
Transcript edited for clarity.
Leslie Reviews Relevant Data for Treatment of Relapsed/Refractory CLL
May 8th 2024During a Case-Based Roundtable® event, Lori A. Leslie, MD, discussed Bruton tyrosine kinase inhibition options for a patient with relapsed/refractory chronic lymphocytic leukemia in the first article of a 2-part series.
Read More
Marks Explores Cardiac Toxicities and Dosing Concerns of BTK Inhibitors in CLL
April 26th 2024During a Case-Based Roundtable® event, Stanley M. Marks, MD, moderated a discussion on the impact of cardiac adverse events on patients who receive a Bruton tyrosine kinase inhibitor for chronic lymphocytic leukemia.
Read More
Considering the Durability of Zanubrutinib in Relapsed/Refractory CLL
April 11th 2024During a Case-Based Roundtable® event, Marc S. Hoffmann, MD, discussed his viewpoints on the use of Bruton tyrosine kinase inhibitors for patients with relapsed/refractory chronic lymphocytic leukemia and the efficacy behind zanubrutinib in the second article of a 2-part series.
Read More
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More